|
| Researchers clarified the role of Orosomucoid 1 (ORM1) in the development and therapy resistance in HCC. [BJBMS] |
|
|
|
| PUBLICATIONSRanked by the impact factor of the journal |
|
|
|
| The authors investigated the safety and efficacy of fazirsiran, an RNA interference therapeutic, in patients with liver disease associated with alpha1-antitrypsin deficiency. [New England Journal of Medicine] |
|
|
|
| Researchers investigated whether changes in the content of essential fatty acid-derived lipid autacoids affected hepatocyte mitochondrial bioenergetics and metabolic efficiency. [Hepatology] |
|
|
|
| Scientists demonstrated that metabolically driven histone hyperacetylation in steatotic hepatocytes could increase DNA damage to initiate carcinogenesis. [Genome Medicine] |
|
|
|
| The authors investigated the mechanisms underlying the activation of DNA damage response during non-alcoholic steatotic liver disease (NAFLD). [Developmental Cell] |
|
|
|
| Researchers reported that little characterized cysteine-rich protein 1 (CRIP1) was upregulated in HCC and associated with poor prognosis. [EMBO Journal] |
|
|
|
| Scientists identified a novel role of DEAD-box helicase 24 (DDX24), a member of the DEAD-box protein family, in promoting HCC progression. [Cancer Research] |
|
|
|
| Investigators found that exposing the endothelium-lined channel to fluid flow led to increased secretion of regeneration-associated factors. [Proceedings of the National Academy of Sciences of the United States of America] |
| |
|
|
| | The authors review augmenter of liver regeneration, a ubiquitous fundamental life protein, and how it was expressed more abundantly in the liver than other organs. [Journal of Hepatology] |
|
|
|
| The authors focused on the progression of in vitro liver models developed for human Plasmodium spp. parasites, provided a brief review on important assay requirements, and lastly presented recommendations to improve models to enhance the discovery process of novel preclinical therapeutics. [Trends in Parasitology] |
| |
|
|
| Alvotech announced the initiation of the company’s confirmatory clinical study for AVT06, a biosimilar candidate to Eylea®. [Alvotech] |
|
|
|
| Horizon Therapeutics plc announced that the FDA has approved the supplemental Biologics License Application expanding the labeling to include KRYSTEXXA® injection co-administered with methotrexate, which will help more people with uncontrolled gout achieve a complete response to therapy. [Horizon Therapeutics plc] |
|
|
|
|
| October 17 – October 20 Palermo (Sicily), Italy |
|
|
|
|
|
| The Chinese University of Hong Kong – Hong Kong, China |
|
|
|
| University of Cambridge – Cambridge, England, United Kingdom |
|
|
|
| Pennsylvania State University – State College, Pennsylvania, United States |
|
|
|
| Baylor College of Medicine – Houston, Texas, United States |
|
|
|
| European Molecular Biology Laboratory – Heidelberg, Germany |
|
|
|
|